| Literature DB >> 24116283 |
Je Hyeong Lee1, Dong Ung Lee, Yeong Shik Kim, Hyun Pyo Kim.
Abstract
The fruits of Foeniculum vulgare (Foeniculi Fructus) have been widely used in Chinese medicine as an antiemetic, ameliorating stomach ailments and as an analgesic. In order to establish its potential for antiallergic use, inhibitory actions of the fruiton 5-lipoxgenase (5-LOX) and β-hexosaminidase release were evaluated. The 70% ethanol extract of this plant material (FR) considerably inhibited 5-LOX-catalyzed leukotriene production from A23187-induced rat basophilic leukemia (RBL)-1 cells. The IC50 was 3.2 μg/ml. From this extract, 12 major compounds including sabinene, fenchone, γ-terpinene, α-pinene, limonene, p-anisylacetone, p-anisylaldehyde, estragole (4-allylanisole), trans-anethole, scopoletin, bergapten and umbelliferone were isolated. And it was found that several terpene derivatives including γ-terpinene and fenchone as well as phenylpropanoid, trans-anethole, showed considerable inhibitory action of 5-LOX. In particular, the IC50 of trans-anethole was 51.6 μ M. In contrast, FR and the isolated compounds did not show considerable inhibitory activity on the degranulation reaction of β-hexosaminidase release from antigen-treated RBL-2H3 cells. Against arachidonic acid-induced ear edema in mice, FR and trans-anethole showed significant inhibition by oral administration at doses of 100-400 mg/kg. In conclusion, FR and several major constituents are 5-LOX inhibitors and they may have potential for treating 5-LOX-related disorders.Entities:
Keywords: 5-lipoxygenase; Allergy; Ear edema; Foeniculum vulgare; trans-anethole
Year: 2012 PMID: 24116283 PMCID: PMC3792194 DOI: 10.4062/biomolther.2012.20.1.113
Source DB: PubMed Journal: Biomol Ther (Seoul) ISSN: 1976-9148 Impact factor: 4.634
Fig. 1.Chemical structures of the active constituents of F. vulgare. (A) Chemical structures of the selected compounds isolated, (B) GC spectrum of the hexane fraction, The retention times were 15.15 (α-pinene), 16.78 (sabinene), 16.93 (β-pinene), 17.52(myrcene), 19.28 (p-cymene), 19.51 (limonene), 19.65 (1,8-cineole), 19.95 (E-ocimene), 21.25 (γ-terpinene), 23.09 (fenchone), 30.33 (estragole), 34.22 (p-anisaldehyde), 36.58 (trans-anethole) and 42.59 min (anisylacetone).
Fig. 2.Effects of the extracts of F. vulgare on 5-LOX and degranulation reaction. (A) Inhibition of 5-LOX catalyzed LT production from A23187-treated RBL-1 cells. (B) Inhibition of β-hexosaminidase release from antigen-treated RBL-2H3 cells. The water extract (○), 70% ethanol extract (●). All points and bars represent arithmetic mean ± SD (n=3), *P<0.01, significantly different from the control group.
Inhibition of the constituents of the fruits of F. vulgare against 5-LOX-catalyzed LT production
| Compounds | % inhibition at 50 μMa |
|---|---|
|
| |
| 5-LOX | |
|
| |
| NDGA | 92.4 |
| Monoterpenes | |
| Sabinene | 22.3 |
| Fenchone | 40.9 (> 50)b |
| γ-Terpinene | 48.3 (>50) |
| α-Pinene | –c |
| Limonene | 9.9 |
| Phenylpropanoids | |
| Anisylacetone | 32.6 (>50) |
| 4-Allylanisole (estragole) | - |
| | 49.1 (51.6) |
| Phenolic | |
| | - |
| Coumarins | |
| Scopoletin | - |
| Bergapten | - |
| Umbelliferone | - |
aAll values are arithmetic mean of % inhibition at 50 μM except NDGA (1 μM). n=3, bThe values of the parenthesis are IC50 vales in μM. c–: not active.
Fig. 3.Inhibition of trans-anethole on 5-LOX-catalyzed LT production.LTC4/D4/E4 (1624.8 ± 59.3 pg/ml) was produced from A23187-treated RBL-1 cells for 15 min incubation. Basal level of LTC4/D4/E4 was 286.0 ± 29.0 pg/ml. All points and bars represent arithmetic mean ± SD (n=3), *p<0.01, significantly different from the control group.
Inhibition of arachidonic acid (AA)-induced ear edema in mice by FR and trans-anethole
| Compounds | Dose (mg/kg)a | Ear thickness increased (mm) | % inhibition |
|---|---|---|---|
|
| |||
| AA-treated | - | 0.080 ± 0.016 | - |
| NDGA | 2b | 0.044 ± 0.013* | 45.0 |
| FR | 100c | 0.044 ± 0.013* | 45.0 |
| 50 | 0.038 ± 0.017* | 52.5 | |
| 200 | 0.036 ± 0.015* | 72.5 | |
aAll compounds were orally treated one hour prior to AA application, except NDGA. bNDGA (2 mg/ear) was treated topically to ears of mice 30 min prior to AA application. cHigher dose than 100 mg/kg could not be tested due to the insolubility of the extract in DMSO. All data are arithmetic means ± SD (n=5). *p<0.01, significantly different from the AA-treated group.